[Two new mutations in the gene that codes for acid alpha-glucosidase in an adolescent with late-onset Pompe disease]

Rev Neurol. 2013 Sep 16;57(6):265-8.
[Article in Spanish]

Abstract

INTRODUCTION. Glycogen storage disease type II, or Pompe disease, is a lysosomal disease with an autosomal recessive pattern of inheritance. Late-onset Pompe disease is a progressive metabolic myopathy caused by decreased activity of the enzyme acid alpha-glucosidase (GAA), which gives rise to reduced degradation and later accumulation of glycogen in the lysosomes and cell cytoplasm. CASE REPORT. A 16-year-old Venezuelan male, diagnosed with late-onset glycogen storage disease type II, or Pompe disease, based on the patient's clinical picture and the biochemical findings. The patient presented unmistakable signs of muscular atrophy in the upper and lower limbs, as well as positive Gowers' sign. Levels of creatinkinase in serum were high. His functional respiratory capacity was diminished. The quantification of the enzymatic activity of acid alpha-glucosidase on filter paper did not show any significant decrease in activity. A molecular genetic analysis revealed the existence of two homozygotic mutations in the gene GAA, c.547-67C>G and c.547-39T>G, both on exon 2 of chromosome 17. According to the human genome database and the review that was undertaken, the changes detected in this patient represent new mutations in the acid alpha-glucosidase gene, GAA. This claim is in agreement with the clinical features and biochemical changes found in the patient. CONCLUSION. A molecular genetic study is mandatory in patients suspected of having this disease.

Title: Dos nuevas mutaciones en el gen que codifica la alfa-glucosidasa acida en un adolescente con enfermedad de Pompe de inicio tardio.

Introduccion. La glucogenosis tipo II o enfermedad de Pompe es una enfermedad lisosomal con un patron de herencia autosomico recesivo. La enfermedad de Pompe de inicio tardio es una miopatia metabolica progresiva causada por una disminucion de la actividad de la enzima alfa-glucosidasa acida (GAA), lo que origina una disminucion de la degradacion y posterior acumulo del glucogeno dentro de los lisosomas y el citoplasma celular. Caso clinico. Adolescente venezolano, de 16 años, diagnosticado de glucogenosis tipo II o enfermedad de Pompe, de comienzo tardio, basado en la clinica del paciente y los hallazgos bioquimicos. La atrofia muscular de los miembros superiores e inferiores era evidente y presentaba maniobra de Gowers positiva. Los niveles sericos de creatincinasa eran elevados. Su capacidad funcional respiratoria estaba disminuida. La cuantificacion de la actividad enzimatica de la GAA en papel de filtro no mostraba una disminucion significativa de la actividad. El analisis genetico molecular revelo la existencia de dos mutaciones en condicion homocigotica en el gen GAA, c.547-67C>G y c.547-39T>G, ambas en el exon 2 del cromosoma 17. De acuerdo con la base de datos del genoma humano y la revision emprendida, los cambios detectados en este paciente representan nuevas mutaciones en el gen GAA. Esta afirmacion esta en concordancia con la clinica y cambios bioquimicos encontrados en el paciente. Conclusion. Es obligatorio el estudio genetico molecular en un paciente en el que se sospecha la enfermedad.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adolescent
  • Age of Onset
  • Alanine Transaminase / blood
  • Aspartate Aminotransferases / blood
  • Biomarkers
  • Chromosomes, Human, Pair 17 / genetics
  • Creatine Kinase / blood
  • Exons / genetics
  • Glucan 1,4-alpha-Glucosidase / genetics*
  • Glycogen Storage Disease Type II / blood
  • Glycogen Storage Disease Type II / diagnosis
  • Glycogen Storage Disease Type II / genetics*
  • Glycogen Storage Disease Type II / pathology
  • Homozygote
  • Humans
  • L-Lactate Dehydrogenase / blood
  • Male
  • Muscle, Skeletal / pathology
  • Mutation, Missense*
  • Phenotype
  • Point Mutation*
  • Sequence Analysis, DNA
  • Venezuela

Substances

  • Biomarkers
  • L-Lactate Dehydrogenase
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Creatine Kinase
  • Glucan 1,4-alpha-Glucosidase